P08.17 Mitotic checkpoint inhibition augments Tumor-Treating-Field (TTField) effects on glioblastoma cells

Por Kessler, A. F.
Publicado no Neuro Oncol (2017)

P09.21 Complete radiological response after subtotal resection in two Gglioblastoma patients treated with Tumor Treating Fields

Por Kessler, A. F., Linsenmann, T.
Publicado no Neuro Oncol (2017)

P14.59 Post-Market Surveillance Data of the EMEA region indicate good tolerability of TTFields in WHO Grade III Glioma

Por Keßler, A F, Ritz, R
Publicado no Neuro Oncol (2019)

P06.06 Is activating transcription factor 5 (ATF5) a new therapeutic target in astrocytomas of different WHO grades and varying biological behavior? An expression analysis

Por Feldheim, J. A., Keßler, A. F.
Publicado no Neuro Oncol (2016)

P08.20 Augmentation of Tumor-Treating-Field (TTField) effects on glioblastoma cells by mitotic checkpoint inhibition

Por Frömbling, G. E., Kessler, A. F.
Publicado no Neuro Oncol (2016)

P14.60 FET PET response upon radiochemotherapy followed by Tumor Treating Fields (TTFields) in a patient with progressive high-grade glioma

Por Keßler, A F, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M
Publicado no Neuro Oncol (2019)

P14.28 First report on the combination of axitinib and Tumor Treating Fields (TTFields) in three patients with recurrent glioblastoma

Por Keßler, A F, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M
Publicado no Neuro Oncol (2019)

O4.06 ANALYSIS OF RAF PROTEINS IN MALIGNANT GLIOMAS

Por Hagemann, C., Gloger, J., Kessler, A.F., Linsenmann, T., Vince, G.H., Ernestus, R., Löhr, M.
Publicado em 2014

P04.33 Effects of Tumor Treating Fields (TTFields) on blood brain barrier (BBB) permeability

Por Kessler, A F, Schaeffer, C, Burek, M, Ruschig, U, Ernestus, R, Löhr, M, Förster, C, Hagemann, C
Publicado no Neuro Oncol (2018)

P01.13 EXPRESSION OF HUMAN ENDOGENOUS RETROVIRUS K (HERV-K) IN HUMAN ASTROCYTIC TUMORS

Por Kessler, A.F., Wiesner, M., Denner, J., Kämmerer, U., Löhr, M., Linsenmann, T., Vince, G.H., Ernestus, R., Hagemann, C.
Publicado em 2014

OS4.3 The BReMen trial: Patients with benign meningioma - is rehabilitation really necessary?

Por Kessler, A F, Krause, K, Al-Shameri, B, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M, Jentschke, E
Publicado no Neuro Oncol (2018)

P11.28 Alteration of blood brain barrier (BBB) permeability by Tumor Treating Fields (TTFields) in vivo

Por Keßler, A F, Salvador, E, Domröse, D, Burek, M, Tempel Brami, C, Voloshin Sela, T, Giladi, M, Ernestus, R, Löhr, M, Förster, C, Hagemann, C
Publicado no Neuro Oncol (2019)

P01.050 Circulating MACC1 transcript plasma levels in glioblastoma patients segregate together with prognostic markers and treatment response

Por Hagemann, C, Neuhaus, N, Dahlmann, M, Kessler, A F, Kobelt, D, Herrmann, P, Eyrich, M, Freitag, B, Freitag, B, Linsenmann, T, Monoranu, C M, Ernestus, R, Löhr, M, Stein, U
Publicado no Neuro Oncol (2018)